A new treatment that underwent clinical trial for a year has proven to be safe and helped reduce the progress of the disease. Researchers from Purdue University designed a molecule that inhibits the eventual formation of amyloid plaque in the brain, which causes the symptoms of Alzheimer’s. This is developed into a drug which was given to volunteers for clinical trial in 2007. The levels of protein amyloid beta is measured in plasma, and is considered a biomarker. Reduction of this protein indicates the effectiveness of the new drug. A second clinical trial is scheduled this year.
Alzheimer’s disease shows its symptoms usually after the age of 60.
